07:22:20 Europe / Stockholm


2023-03-01 14:48:00

Redeye provides an update in relation to RLS’ Q4 2022 report. The report did not include any major surprises in our view; however, we expect quarterly reports to become more interesting as we expect sales to ramp up during 2023. We make some changes in our OPEX assumptions, include a future capital raising, and increase the WACC to 13.5% (12.5%) because of an updated Redeye Rating. The changes result in a new fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/